Article: | MedLuna.com

Overview

Journal CMAJ

Date 2021 Oct 5

PMID 34607850

Authors

Anne Pham-Huy

Karina A Top

Cora Constantinescu

Cynthia H Seow

Darine El-Chaar

Affiliations

Soon will be listed here.

References

Klink D, van Elburg R, Schreurs M, van Well G . Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008; 2008:271363. PMC: 2438602. DOI: 10.1155/2008/271363. View

Cortes X, Borras-Blasco J, Antequera B, Fernandez-Martinez S, Castera E, Martin S . Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther. 2016; 42(2):234-236. DOI: 10.1111/jcpt.12492. View

Buyon J, Kim M, Guerra M, Laskin C, Petri M, Lockshin M . Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med. 2015; 163(3):153-63. PMC: 5113288. DOI: 10.7326/M14-2235. View

Mahadevan U, Long M, Kane S, Roy A, Dubinsky M, Sands B . Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2020; 160(4):1131-1139. PMC: 7956164. DOI: 10.1053/j.gastro.2020.11.038. View

Zelinkova Z, de Haar C, de Ridder L, Pierik M, Kuipers E, Peppelenbosch M . High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011; 33(9):1053-8. DOI: 10.1111/j.1365-2036.2011.04617.x. View

Rowan C, Cullen G, Mulcahy H, Keegan D, Byrne K, Murphy D . Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation. J Crohns Colitis. 2017; 12(3):376-378. DOI: 10.1093/ecco-jcc/jjx141. View

Flanagan E, Gibson P, Wright E, Moore G, Sparrow M, Connell W . Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020; 52(10):1551-1562. DOI: 10.1111/apt.16102. View

Tsao N, Hanley G, Lynd L, Amiri N, De Vera M . Risk of congenital anomalies in infants born to women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. Clin Exp Rheumatol. 2019; 37(6):976-982. View

Mariette X, Forger F, Abraham B, Flynn A, Molto A, Flipo R . Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2017; 77(2):228-233. PMC: 5867410. DOI: 10.1136/annrheumdis-2017-212196. View

10.

Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L . Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol. 2016; 116:7-12. DOI: 10.1016/j.jri.2016.04.284. View

11.

Chakravarty E, Murray E, Kelman A, Farmer P . Pregnancy outcomes after maternal exposure to rituximab. Blood. 2010; 117(5):1499-506. DOI: 10.1182/blood-2010-07-295444. View

12.

Moens A, van der Woude C, Julsgaard M, Humblet E, Sheridan J, Baumgart D . Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2019; 51(1):129-138. DOI: 10.1111/apt.15539. View

13.

Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K . BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford). 2016; 55(9):1698-702. DOI: 10.1093/rheumatology/kev405. View

14.

Johnsson A, Avlund S, Grosen A, Julsgaard M . Chicken pox infection in a three months old infant exposed in utero to Adalimumab. J Crohns Colitis. 2012; 7(3):e116-7. DOI: 10.1016/j.crohns.2012.07.020. View

15.

Gonczi L, Bessissow T, Lakatos P . Disease monitoring strategies in inflammatory bowel diseases: What do we mean by "tight control"?. World J Gastroenterol. 2019; 25(41):6172-6189. PMC: 6848014. DOI: 10.3748/wjg.v25.i41.6172. View

16.

Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Friedman S, Norgard B . The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017; 23(6):1011-1018. DOI: 10.1097/MIB.0000000000001102. View

17.

Fritzsche J, Pilch A, Mury D, Schaefer C, Weber-Schoendorfer C . Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol. 2012; 46(8):718-9. DOI: 10.1097/MCG.0b013e31825f2807. View

18.

Tsao N, Sayre E, Hanley G, Sadatsafavi M, Lynd L, Marra C . Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study. Ann Rheum Dis. 2018; 77(6):869-874. DOI: 10.1136/annrheumdis-2018-213023. View

19.

Matro R, Martin C, Wolf D, Shah S, Mahadevan U . Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018; 155(3):696-704. DOI: 10.1053/j.gastro.2018.05.040. View

20.

Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M . Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019; 156(5):1508-1524. DOI: 10.1053/j.gastro.2018.12.022. View